EUCTR2013-001746-33-BE进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 514
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Subject is between the ages of 18 to 75 years
- •2) Diagnosis of colonic, ileocolonic, or ileal Crohn's disease for = 3 months prior to Baseline and confirmed by endoscopy during the Screening period or endoscopy performed within 45 days before Baseline.
- •3) Crohn's Disease Activity Index (CDAI) = 220 and = 450 at Baseline despite concurrent or prior treatment with a full oral corticosteroids and/or immunosuppressants
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 540
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1) Subject with ulcerative colitis or indeterminate colitis
- •2) Subject who has had surgical bowel resections within the past 6 months or is planning resection
- •3) Subject with an ostomy or ileoanal pouch
- •4) Subject with bowel stricture or abdominal or peri-anal abscess
- •5) Subject who has short bowel syndrome
- •6) Chronic recurring infections or active TB
研究者
相似试验
进行中（未招募）
1 期
A Blinded Study to Evaluate Higher Versus Standard Adalimumab doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal UlceratioMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's diseaseEUCTR2013-001746-33-ATAbbVie Deutschland GmbH & Co. KG500
已完成
3 期
Efficacy and Safety Study of Alogliptin Compared to Glipizide in Elderly DiabeticsCTRI/2009/091/000123Takeda Global Research & Development Centre (Europe) Ltd (TGRD)61 AldwychLondon WC2B 4AE United Kingdom
进行中（未招募）
1 期
A Blinded Study to Evaluate Higher Versus Standard Adalimumab doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal UlceratioCrohn's diseaseMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-001746-33-CZAbbVie Deutschland GmbH & Co. KG600
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic ControlType II Diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003548-32-LTMerck & Co., Inc.500
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients with Type 2 DMMedDRA version: 7.0Level: LLTClassification code 10045242Type 2 Diabetes MellitusEUCTR2004-000313-19-HUMerck & Co., Inc.18